VDAC1 and Miyoshi myopathy: Together with the information that expression of VDAC1 in patients with stage III was significantly higher than that in patients with stage I and stage II [144], one could imply that VDAC1 seems to accelerate MM tumor growth, while increase susceptibility to apoptosis, making it a good target candidate for MM therapy.